Patent US3904324A successfully refreshed from Google Patents.
Patent US3028579A successfully refreshed from Google Patents.
Patent US4786509A successfully refreshed from Google Patents.
US4786509A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Dry sustained release theophylline oral formulation
Assignee: Merck Sharp & Dohme LLC
•
Filing: 1987-05-18
•
Granted: 1988-11-22
•
Expires: 2007-05-18
Abstract
Abstract A sustained release theophylline containing oral dosage formulation comprising theophylline containing micropellets coated with from about 0.5% to about 2% by weight of a pharmaceutically acceptable water-insoluble film former, preferably ethyl cellulose and having first order release. The formulation is an improvement over theophylline containing micropellets coated with two film formers which have zero order release. The oral dosage formulation has superior non-fasting release and absorption characteristics when compared to the zero order release formulation.
Inventors
- 👤 Richard Chang
- 👤 Robert P. Giannini
- 👤 Charles Hsaio
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 20:59
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/48; A61K9/50; A61K9/5073; A61K9/5078; A61K31/00; A61K31/33; A61K31/395; A61K31/495; A61K31/505; A61K31/519; A61K31/52
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
47 words
A first order sustained release theophylline composition comprising theophylline-containing micropellets having on the outside surface thereof a coating consisting of a pharmaceutically acceptable water-insoluble single film former present in an amount of from about 0.5% to about 2.0% by weight based on the weight of said micropellets.
Claim 2
Dependent Claim
47 words
A first order sustained release theophylline composition comprising theophylline-containing micropellets having on the outside surface thereof a coating consisting of a pharmaceutically acceptable water-insoluble single film former present in an amount of from about 0.5% to about 2.0% by weight based on the weight of said micropellets.
Claim 3
Dependent Claim
11 words
A composition of claim 1 wherein said coating is ethyl cellulose.
Claim 4
Dependent Claim
15 words
A composition of claim 2 wherein the ethyl cellulose coating is about 1.5% by weight.
Claim 5
Dependent Claim
67 words
A first-order sustained release unit dosage form of theophylline comprising an easily openable capsule having therein a plurality of theophylline-containing micropellets, the amount of micropellets in said capsule comprising a dosage unit of theophylline, wherein each of said micropellets have a coating thereon of from about 0.5% to about 2.0% by weight based on the weight of said micropellets of a single pharmaceutically acceptable water-insoluble film former.
Claim 6
Dependent Claim
67 words
A first-order sustained release unit dosage form of theophylline comprising an easily openable capsule having therein a plurality of theophylline-containing micropellets, the amount of micropellets in said capsule comprising a dosage unit of theophylline, wherein each of said micropellets have a coating thereon of from about 0.5% to about 2.0% by weight based on the weight of said micropellets of a single pharmaceutically acceptable water-insoluble film former.
Claim 7
Dependent Claim
14 words
A unit dosage form of claim 4 wherein the film former is ethyl cellulose.
Claim 8
Dependent Claim
18 words
A unit dosage form of claim 5 wherein the amount of ethylcellulose coating is about 1.5% by weight.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-11-22 | 1992-05-23 | 1992-11-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-11-22 | 1996-05-23 | 1996-11-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-11-22 | 2000-05-23 | 2000-11-22 | $7700.00 | Window Closed / Lapsed |